A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)

Part of paid clinical trials in St Louis, Missouri.

Sponsor
Alpha Cognition, Inc
Study ID
NCT07633470
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Zunveyl® — DRUG
    Zunveyl® delayed release oral tablets.

Study Details

The primary purpose of this study is to evaluate the safety and tolerability of Zunveyl® over 12 weeks of routine clinical use in adults with mild to moderate Alzheimer's disease.

Key Dates

Start date
Jun 30, 2026
Status verified
Jun 2026
Primary completion
Apr 30, 2027
Completion
Apr 30, 2027

Study Design

Enrollment
150 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Zunveyl®
    Participants will receive Zunveyl® at a dose of 5 milligrams (mg), delayed release tablets, orally, twice daily (BID) from Weeks 1 to 4, followed by 10 mg, delayed release tablets, orally, BID for the subsequent Weeks 5 to12.

Primary Outcome Measure

Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: From Week 1 up to Week 12 ]

Central Contacts

Locations (1)

FacilityCityStateZIP
Tekton Research Saint Louis PsychiatrySt LouisMissouri63128

Find similar trials in St Louis, MO

By condition
Alzheimer's disease
By specialty
NeurologyDementia careBrain disordersGeriatrics
By research site
Tekton Research Saint Louis Psychiatry· St Louis, MO

Related Studies